These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15958845)

  • 1. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
    Lacombe K; Pacanowski J; Meynard JL; Trylesinski A; Girard PM
    AIDS; 2005 Jul; 19(10):1107-8. PubMed ID: 15958845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
    Barrios A; Rendón A; Negredo E; Barreiro P; Garcia-Benayas T; Labarga P; Santos J; Domingo P; Sánchez-Conde M; Maida I; Martín-Carbonero L; Núñez M; Blanco F; Clotet B; Sambeat MA; Gil P; Gonzalez-Lahoz J; Cooper D; Soriano V
    AIDS; 2005 Mar; 19(6):569-75. PubMed ID: 15802975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
    Kakuda TN; Anderson PL; Becker SL
    AIDS; 2004 Dec; 18(18):2442-4. PubMed ID: 15622326
    [No Abstract]   [Full Text] [Related]  

  • 4. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Barreiro P; Soriano V
    J Antimicrob Chemother; 2006 May; 57(5):806-9. PubMed ID: 16531427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):427-8. PubMed ID: 15097160
    [No Abstract]   [Full Text] [Related]  

  • 6. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    Int J STD AIDS; 2005 Sep; 16(9):646-8. PubMed ID: 16176639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
    García-Benayas T; Rendón AL; Rodríguez-Novóa S; Barrios A; Maida I; Blanco F; Barreiro P; Rivas P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):333-7. PubMed ID: 16623636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
    Callens S; De Schacht C; Huyst V; Colebunders R
    J Infect; 2003 Aug; 47(2):188-9. PubMed ID: 12860159
    [No Abstract]   [Full Text] [Related]  

  • 10. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
    Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
    Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.
    Ripamonti D; Maggiolo F; Suter F
    AIDS; 2007 May; 21(8):1059-60. PubMed ID: 17457107
    [No Abstract]   [Full Text] [Related]  

  • 12. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
    Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.
    Claas GJ; Jülg B; Goebel FD; Bogner J
    Eur J Med Res; 2007 Feb; 12(2):54-60. PubMed ID: 17369118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal toxicity in HIV-infected patients receiving HAART including tenofovir].
    Madeddu G; Quirino T; Carradori S; Ricci E; Grosso C; Penco G; De Socio G; Rossella E; Palvarini L; Marconi P; Melzi S; Mura MS; Bonfanti P;
    Infez Med; 2006 Sep; 14(3):125-34. PubMed ID: 17127826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
    Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
    AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
    Negredo E; Moltó J; Burger D; Viciana P; Ribera E; Paredes R; Juan M; Ruiz L; Puig J; Pruvost A; Grassi J; Masmitjà E; Clotet B
    AIDS; 2004 Feb; 18(3):459-63. PubMed ID: 15090798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
    Negredo E; Moltó J; Muñoz-Moreno JA; Pedrol E; Ribera E; Viciana P; Galindos MJ; Miralles C; Burger D; Rodriguez Fumaz C; Puig J; Gel S; Rodríguez E; Videla S; Ruiz L; Clotet B
    Antivir Ther; 2004 Jun; 9(3):335-42. PubMed ID: 15259896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir-related nephrotoxicity in HIV-infected patients.
    Barrios A; García-Benayas T; González-Lahoz J; Soriano V
    AIDS; 2004 Apr; 18(6):960-3. PubMed ID: 15060449
    [No Abstract]   [Full Text] [Related]  

  • 19. Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
    Silkiss RZ; Lee H; Gills Ray VL
    Arch Ophthalmol; 2009 Mar; 127(3):345-6. PubMed ID: 19273808
    [No Abstract]   [Full Text] [Related]  

  • 20. Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
    Maggiolo F; Roat E; Pinti M; Nasi M; Gibellini L; De Biasi S; Airoldi M; Ravasio V; Mussini C; Suter F; Cossarizza A
    Antivir Ther; 2010; 15(1):51-9. PubMed ID: 20167991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.